Zhaoke Ophthalmology says presbyopia eye drop YUVEZZI meets primary endpoint in China Phase II trialPUBT·9 hours ago06622+1.61%
China Qidian Guofeng FY26 H1 loss widens to RMB 36.77 million; revenue rises 29.4% to RMB 235.47 millionPUBT·Aug 28 at 09:52 AM01280+6.67%
Zhaoke Ophthalmology signs exclusive distribution deal with Pharmentum Biopharma for epinastine eye drops in ChinaPUBT·Aug 12 at 08:55 AM06622+1.61%
The great pivot to AI compute, and a mid-cap identity crisisGlobal Report·Jul 22 at 09:17 AM02661+3.42%01070-1.94%
Zhaoke Ophthalmology says Macau regulator approves presbyopia eye drop YUVEZZIPUBT·Jul 20 at 04:02 AM06622+1.61%
CICC's Mega-Merger Moves Forward While Sinotruk Hits the Gas on EV ExportsGlobal Report·Jul 19 at 09:12 AM01066+1.56%03908+2.91%
Zhaoke Ophthalmology Wins Boao Approval for First Innovative Presbyopia Drug in ChinaTip Ranks·Jul 7 at 04:07 AM06622+1.61%
Kingmaker Footwear files HKEX next-day disclosure return on share repurchase for cancellationPUBT·Jul 6 at 10:03 AM01170-6.82%
Zhaoke Ophthalmology files HKEX next-day disclosure return on share repurchase for cancellationPUBT·Jul 3 at 12:58 AM06622+1.61%
Zhaoke Ophthalmology files HKEX next-day return disclosing share repurchase for cancellationPUBT·Jun 24 at 12:47 AM06622+1.61%
Zhaoke Ophthalmology files HKEX next-day disclosure return on share repurchase for cancellation at HKD 2.54-2.54PUBT·Jun 23 at 01:00 AM06622+1.61%
Zhaoke Ophthalmology’s Myopia Drug NVK002 Accepted for Australian TGA EvaluationTip Ranks·Jun 15 at 04:38 AM06622+1.61%
Zhaoke Ophthalmology Shareholders Approve All Resolutions at 2026 AGMTip Ranks·May 15 at 01:44 PM06622+1.61%
Looking for overseas growth, Aier Eye seeks Hong Kong listingBambooWorks·Apr 30 at 12:50 PM300015+1.45%06622+1.61%
